On November 4, 2023, the "Apremilast Treatment Silver" event was hosted by the Key Laboratory of Dermatology of the Ministry of Education, the Dermatology and Skin Beauty Branch of the Chinese Medical Equipment Association, and the Psoriasis Committee of the Dermatology and Venereology Branch of the Chinese Medical Association. The consultation and finalization meeting for the Expert Guidance on Chips Disease (hereinafter referred to as the "Guidance") was successfully held in Suzhou. This conference invites well-known psoriasis experts in China to attend the conference and participate in discussions.

Professor Zhang Xuejun, Director of the Institute of Dermatology of Fudan University and Director of the Collaborative Innovation Center for Difficult and Severe Dermatology of Anhui Medical University, served as the chairman of the meeting and delivered a speech. Professor Zhang Xuejun first welcomed the active participation of all participating experts and expressed his gratitude to the experts for their collaborative work in writing the consensus. Professor Zhang pointed out that in the past five years, the application of biological agents and small molecule targeted drugs has brought about earth-shaking changes in the treatment of psoriasis. In order to solve the unsatisfactory problem in the clinical treatment of psoriasis in China, apremilast was introduced into China as the first batch of overseas new drugs with urgent clinical needs. It was approved for marketing in 2021 and included in the 2023 medical insurance catalog. When Apremilast was approved, there was no clinical trial data based on the Chinese population. With its widespread use in China, medical workers have many clinical problems regarding the treatment of psoriasis with Apremilast. There is an urgent need for "Apremilast" Expert Guidance on the Treatment of Psoriasis" guides clinical medication use.

Professor Li Min from Dushuhu Hospital Affiliated to Suzhou University introduced the background and content of the first draft of the "Guiding Opinions". The "Guiding Opinions" consists of a preface, main text, summary and references. The main text covers the mechanism of action and pharmacological properties of Apremilast, the efficacy and safety of Apremilast in the treatment of psoriasis, indications, contraindications, usage and dosage, medication for special groups and other related content.

Professor Zheng Min from Zhejiang University School of Medicine presided over the discussion session of the "Guidance Opinions" solicitation and finalization meeting. Experts attending the meeting discussed the first draft of the "Guidance Opinions", shared their experience with apremilast in clinical practice, and put forward relevant suggestions and revisions. Experts believe that the formulation of this "Guideline" provides reference and guidance for the treatment of psoriasis and is practical. However, the first draft of this edition still needs further review and revision in terms of writing standards, data supplementation, references, etc.

Finally, Professor Zhang Xuejun pointed out in the summary of the conference that this meeting had an in-depth discussion and exchange on the first draft of the "Expert Guidance on the Treatment of Psoriasis with Apremilast." The next step will be to further improve this "Guiding Opinions" based on the suggestions and revisions of participating experts, including indications, contraindications, treatment plans, applicable groups, etc. Provide clinicians and patients with more scientific and standardized treatment references to better serve psoriasis patients.